As of close of business last night, Credo Technology Group Holding Ltd’s stock clocked out at $19.44, down -9.33% from its previous closing price of $21.44. On the day, 2109745 shares were traded.
Ratios:
To gain a deeper understanding of CRDO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8139.38. For the most recent quarter (mrq), Quick Ratio is recorded 11.94 and its Current Ratio is at 12.72. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on February 28, 2024, Reiterated its Market Perform rating but revised its target price to $24 from $20 previously.
On November 30, 2023, TD Cowen reiterated its Market Perform rating and also lowered its target price recommendation from $16 to $20.
On October 02, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $18.Barclays initiated its Overweight rating on October 02, 2023, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’27 when Brennan William Joseph sold 15,000 shares for $17.71 per share. The transaction valued at 265,662 led to the insider holds 3,867,421 shares of the business.
Brennan William Joseph sold 15,000 shares of CRDO for $216,762 on Oct 24 ’24. The Pres & Chief Executive Officer now owns 3,927,421 shares after completing the transaction at $14.45 per share. On Apr 11 ’24, another insider, Lam Yat Tung, who serves as the Chief Operating Officer of the company, sold 78,127 shares for $22.72 each. As a result, the insider received 1,774,709 and left with 720,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 19.32 while its Price-to-Book (P/B) ratio in mrq is 5.94.
Stock Price History:
Over the past 52 weeks, CRDO has reached a high of $23.90, while it has fallen to a 52-week low of $7.20.
Shares Statistics:
A total of 148.65M shares are outstanding, with a floating share count of 126.43M. Insiders hold about 22.57% of the company’s shares, while institutions hold 66.81% stake in the company.
Earnings Estimates
As of right now, Cardiff Oncology, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $19.44, with high estimates of $34.15 and low estimates of $23.35.
Analysts are recommending an EPS of between $Communication Services and $Healthcare for the fiscal current year, implying an average EPS of $Technology.
